“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's ...

AbbVie is a strong investment opportunity with growth potential, dividend income, and a diverse drug portfolio. Find out why ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.

Tavapadon hit the primary endpoint in one phase 3 trial in April, before AbbVie closed the takeover, and racked up another victory in September. AbbVie completed the set Monday by reporting data from ...

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

US pharma major AbbVie announced positive top-line results from its pivotal Phase III TEMPO-2 trial evaluating ...

The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

Hello from San Diego, where I always happen to be, but where this weekend I had the delight of hanging out with coworkers ...